Analysed Ultragenyx Pharmaceutical Inc (RARE:NASDAQ) News Sources
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, Deadline
The Malaysian Reserve
Ultragenyx Pharmaceutical Inc.: Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen ...
FinanzNachrichten.de
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure ...
The Bakersfield Californian
Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
Yahoo Finance
What is the current price of Ultragenyx Pharmaceutical Inc (RARE:NASDAQ)?
The current price of Ultragenyx Pharmaceutical Inc (RARE:NASDAQ) is $23.04.
Ultragenyx Pharmaceutical Inc (RARE:NASDAQ) absolute price change since previous trading day?
The absolute price change of Ultragenyx Pharmaceutical Inc (RARE:NASDAQ) since the previous trading day is $0.13.
Ultragenyx Pharmaceutical Inc (RARE:NASDAQ) percentage price change since previous trading day?
The percentage price change of Ultragenyx Pharmaceutical Inc (RARE:NASDAQ) since the previous trading day is 0.57%.
What is This Week's average sentiment score for Ultragenyx Pharmaceutical Inc (RARE:NASDAQ)?
This Week's average sentiment score for Ultragenyx Pharmaceutical Inc (RARE:NASDAQ) is 61 out of 100.
What is This Week's average sentiment for Ultragenyx Pharmaceutical Inc (RARE:NASDAQ)?
This Week's sentiment for Ultragenyx Pharmaceutical Inc (RARE:NASDAQ) is .
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.